Novel immunosuppressive drugs in renal transplantation
Basić-Jukić, N.; Kes, P.
Acta Medica Croatica Casopis Hravatske Akademije Medicinskih Znanosti 65(4): 361-364
2011
ISSN/ISBN: 1330-0164 PMID: 22359909 Document Number: 652745
The major targets of novel immunosuppressive protocols are decreased toxicity and improved graft and patient survival. Over the last decade, several drugs have been demonstrated to have potential beneficial effect in transplantation. Most of these agents are currently in phase II or III of clinical studies.
Document emailed within 1 workday
Related Documents
Nakagawa, Y.; Ikeda, M.; Tasaki, M.; Saito, K.; Takahashi, K. 2013: The new immunosuppressive drugs for renal transplantation: inhibitors of the mammalian target of rapamycin (mTOR) and anti-thymocyte globulin (Thymoglobulin) Nihon Jinzo Gakkai Shi 55(2): 112-118Devergie, A.; Esperou, H.; Traineau, R.; Varrin, F.; Lehn, P.; Gluckman, E. 1989: Role of immunosuppressive drugs for prevention of graft-v-host disease after bone marrow transplantation Nouvelle Revue Francaise d'Hematologie 31(2): 73-75
Koyama, I.; Amemiya, H.; Taguchi, Y.; Watanabe, T.; Nagashima, N.; Suzuki, S.; Omoto, R. 1991: Prophylactic use of deoxyspergualin in a quadruple immunosuppressive protocol in renal transplantation Transplantation Proceedings 23(1 Part 2): 1096-1098
Heering, P.; Westhoff, A.; Ivens, K.; Kutkuhn, B.; Grabensee, B. 1994: Reduction of immunosuppressive therapy after renal transplantation: a randomized study Transplantation Proceedings 26(5): 2530-2532
Eklund, B.; Ahonen, J.; Häyry, P.; Kauste, A.; von Willebrand, E.; Lindström, B.L. 1981: Comparison of two different immunosuppressive dosages of methylprednisolone in clinical renal transplantation Scandinavian Journal of Urology and Nephrology. Supplementum 64: 179-184
Caletti, C.; Granata, S.; Tomei, P.; Dalla Gassa, A.; Lupo, A.; Zaza, G. 2015: Pharmacogenetics: a promising tool to personalize immunosuppressive therapy in renal transplantation Giornale Italiano di Nefrologia: Organo Ufficiale Della Societa Italiana di Nefrologia 32(3)
Heaf, J. 1993: Bone marrow function during quadruple immunosuppressive therapy after renal transplantation Clinical Nephrology 40(6): 332-338
Gupta, K.L.; Ghosh, A.K.; Kochhar, R.; Jha, V.; Chakrabarti, A.; Sakhuja, V. 1994: Esophageal candidiasis after renal transplantation: comparative study in patients on different immunosuppressive protocols American Journal of Gastroenterology 89(7): 1062-1065
Elli, A.; Rivolta, R.; Palazzi, P.; Mascaretti, L.; Puglisi, G.; Parenti, M.; Sioli, V.; Di Palo, F.Q. 1990: Deflazacort versus 6-methylprednisolone in renal transplantation: immunosuppressive activity and side effects Transplantation Proceedings 22(4): 1689-1690
Brocard, J.F.; Farahmand, H.; Fassi, S.; Plaisant, B.; Fries, E.; Cantarovich, M.; Bismuth, A.; Lambert, T.; Hiesse, C.; Lantz, O. 1989: Attempt at depletion of anti-HLA antibodies in sensitized patients awaiting transplantation using extracorporeal immunoadsorption, polyclonal IgG, and immunosuppressive drugs Transplantation Proceedings 21(1 Part 1): 733-734
Pallardo, L.M.; Sanchez, J.; Garcia, J.; Moreno, R.F.; Rochera, A.; Cabezuelo, J. 1988: Low doses of cyclosporine, azathioprine, and prednisone in renal transplantation: immunosuppressive efficacy and reduced nephrotoxicity Transplantation Proceedings 20(5 Suppl 6: 26-27
Ruffault, A.; Fauconnier, B.; Cartier, F.; Launois, B. 1975: Herpes simplex virus antibodies in 18 patients submitted to immunosuppressive agents after renal transplantation Pathologie-Biologie 23(5): 371-374
Canafax, D.M.; Carleton, B.C.; Matas, A.J.; Payne, W.D.; Dunn, D.L.; Sutherland, D.E.; Najarian, J.S. 1993: Effects of three immunosuppressive drug protocols on cadaver renal transplantation costs after 4 years of therapy Transplantation Proceedings 25(1 Pt 2): 1692-1693
Kovarik, J.M.; Rawlings, E.; Sweny, P.; Fernando, O.; Moore, R.; Griffin, P.J.; Fauchald, P.; Albrechtsen, D.; Sodal, G.; Nordal, K.; Amlot, P.L. 1996: Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHi 621 in renal transplantation Transplantation Proceedings 28(2): 913-914
Yun, Y.S.; Kim, B.J.; Hong, S.P.; Lee, T.W.; Lim, C.G.; Kim, M.J. 1996: Changes of bone metabolism indices in patients receiving immunosuppressive therapy including low doses of steroids after renal transplantation Transplantation Proceedings 28(3): 1561-1564
Berns, J.S.; Ford, P.A. 1997: Renal toxicities of antineoplastic drugs and bone marrow transplantation Seminars in Nephrology 17(1): 54-66
Koehntop, D.E.; Noormohamed, S.E.; Fletcher, C.V. 1994: Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation PharmacoTherapy 14(5): 592-599
Archambault-Couture, L.; Beaudry, C.; Legresley, L.P.; Laplante, L. 1979: Neoplasms and renal transplantation. Study at the renal transplantation unit of Maisonneuve-Rosemont Hospital L'Union Medicale du Canada 108(6): 681-684
Rojas-García, P.; Alberú-Gómez, J.; Medina-Franco, H. 2010: Breast fibroadenomas associated with immunosuppressive drugs American Surgeon 76(6): E48-E49
Dhawan, A.; Mack, D.R.; Langnas, A.N.; Shaw, B.W.; Vanderhoof, J.A. 1995: Immunosuppressive drugs and hypertrophic cardiomyopathy Lancet 345(8965): 1644-1645